Adjunctive Dapagliflozin Improves Glycemic Control in T1D
Dapagliflozin, when used as adjunct treatment to insulin, improves glycemic control in patients with type 1 diabetes.
Type 1 diabetes predisposes children and adults to autoimmune diseases, which can impair glucose metabolism and interfere with insulin therapy.
Pregnant women with T1D who received MDI therapy had a larger decrease in HbA1c levels and were less likely to report gestational hypertension, neonatal hypoglycemia, and NICU admissions than women ...
After 52 weeks, dapagliflozin was well tolerated and led to a clinically relevant improvement in glycemic control and weight loss without additional risk for hypoglycemia.